CancerGuard™
Multi-Cancer Early Detection
Pivotal StudiesActive
Key Facts
About Exact Sciences
Exact Sciences is a $20+ billion market cap leader in cancer diagnostics, driven by a mission to prevent, detect earlier, and guide treatment for cancer. Its success is anchored by the dominant Cologuard® colorectal cancer screening test and the globally recognized Oncotype DX® genomic test suite. The company's strategy focuses on expanding its integrated oncology portfolio, notably through the launch of its multi-cancer early detection test, CancerGuard™, and leveraging strategic partnerships like the one with Abbott for enhanced global scale. This positions Exact Sciences to address the full cancer care continuum from screening to treatment guidance.
View full company profileTherapeutic Areas
Other Multi-Cancer Early Detection Drugs
| Drug | Company | Phase |
|---|---|---|
| ALMANAC Study | Guardant Health | Research |
| Ausel Cancer Test | Ausel Cancer Innovation | Pre-clinical |
| GAGome for MCED | Elypta | Clinical Validation |
| Rivela MCED Test | EXOSOMICS | Pre-clinical |
| PATHFINDER 2 | GRAIL | Interventional Study |
| REACH/Galleri-Medicare Study | GRAIL | Prospective Cohort Study |
| REFLECTION Study | GRAIL | Observational Study |
| SUMMIT Study | GRAIL | Observational Cohort Study |
| PATHFINDER Study | GRAIL | Interventional Study |
| MCED Test | Mainz Biomed | Research Collaboration |